Laurien J Zeverijn

Division of Molecular Oncology and Immunology Netherlands Cancer Institute

Claim

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 52 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

时间

引用量

主题

期刊级别

合作者

合作机构

Supplementary Table S1 from the Innate Immune Landscape of Dmmr/msi Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol

Laurien J. Zeverijn,Birgit S. Geurts,Thomas W. Battaglia,Jade M. van Berge Henegouwen,Gijs F. de Wit,Louisa R. Hoes,Hanneke van der Wijngaart,Vincent van der Noort,Paul Roepman,Wendy W.J. de Leng,Anne M.L. Jansen,Myriam Chalabi,Carla M.L. van Herpen,Lot A. Devriese,Frans L.G. Erdkamp,Mariette Labots,Maja J.A. de Jonge,Emile D. Kerver,Adriaan D. Bins,Lindsay V.M. Leek,Jessica C.L. Notohardjo,Alfonsus J.M. van den Eertwegh,Lodewyk F.A. Wessels,Henk M.W. Verheul,Hans Gelderblom,Joris van de Haar,Emile E. Voest

crossref（2024）

Cited0Views0Bibtex

A Pan-Cancer Analysis of the Microbiome in Metastatic Cancer

Thomas W. Battaglia,Iris L. Mimpen,Joleen J. H. Traets,Arne van Hoeck,Laurien J. Zeverijn,Birgit S. Geurts,Gijs F. de Wit,Michael Noe,Ingrid Hofland,Joris L. Vos,Sten Cornelissen,Maartje Alkemade,Annegien Broeks,Charlotte L. Zuur,Edwin Cuppen,Lodewyk Wessels,Joris van de Haar,Emile Voest

Cell（2024）

Cited14Views0WOSBibtex

Supplementary Table S1 from Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol

Jade M. van Berge Henegouwen,Laurien J. Zeverijn,Birgit S. Geurts,Louisa R. Hoes,Hanneke van der Wijngaart,Vincent van der Noort,Alwin D.R. Huitema,Filip Y.F. de Vos,Katrien Grünberg,Haiko J. Bloemendal,Henk M.W. Verheul,Emile E. Voest,Hans Gelderblom

crossref（2024）

Cited0Views0Bibtex

Figure S1. Accrual and Follow-Up1 from Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol

Karlijn Verkerk, Tijmen J.W.T. van der Wel,Laurien J. Zeverijn,Birgit S. Geurts,Ilse A.C. Spiekman,Gijs F. de Wit,Paul Roepman,Anne M.L. Jansen,Vincent van der Noort, Egbert F. Smit,Ann Hoeben,Lizza E.L. Hendriks,Michel M. van den Heuvel,Berber Piet,Gerarda J.M. Herder,Sayed M.S. Hashemi,Hans Gelderblom,Henk M.W. Verheul,Emile E. Voest,Adrianus J. de Langen

crossref（2024）

Cited0Views0Bibtex

Table S4. Differential Expression4 from Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non–Small Cell Lung Cancer—Results from the Drug Rediscovery Protocol

crossref（2024）

Cited0Views0Bibtex

Figure S4 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol

Birgit S. Geurts,Laurien J. Zeverijn,Lindsay V.M. Leek,Jade M. van Berge Henegouwen,Louisa R. Hoes,Hanneke van der Wijngaart,Vincent van der Noort,Joris van de Haar,Annemiek van Ommen-Nijhof,Marleen Kok,Paul Roepman,Anne M.L. Jansen,Wendy W.J. de Leng,Maja J.A. de Jonge,Ann Hoeben,Carla M.L. van Herpen,Hans M. Westgeest,Lodewyk F.A. Wessels,Henk M.W. Verheul,Hans Gelderblom,Emile E. Voest

crossref（2024）

Cited0Views0Bibtex

Supplementary Table S2 from the Innate Immune Landscape of Dmmr/msi Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol

crossref（2024）

Cited0Views0Bibtex

Supplementary Figure S1 from the Innate Immune Landscape of Dmmr/msi Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol

crossref（2024）

Cited0Views0Bibtex

Figure S3 from Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol

crossref（2024）

Cited0Views0Bibtex

Supplementary Table S6 from the Innate Immune Landscape of Dmmr/msi Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol

crossref（2024）

Cited0Views0Bibtex

Author Statistics

#Papers: 52

#Citation: 250

H-Index: 7

G-Index: 15

Sociability: 5

Diversity: 1

Activity: 135

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn